We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Unlikely to Approve More Biogenerics Without Pressure
FDA Unlikely to Approve More Biogenerics Without Pressure
June 16, 2006
Drug companies will likely have to fight the FDA in court to be able to market follow-on biologics, like Sandoz’ recombinant human growth hormone Omnitrope, according to one patent attorney.